Activated mast cells in periprosthetic joint infection-associated tissue.
mast cells
non-infectious arthroplasty failure
periprosthetic joint infection
periprosthetic tissues
tryptase
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
10
03
2023
accepted:
31
07
2023
medline:
6
9
2023
pubmed:
1
9
2023
entrez:
1
9
2023
Statut:
epublish
Résumé
Periprosthetic joint infection (PJI) is a devastating complication of total joint arthroplasty surgery. Increased densities of activated mast cells have been predicted to be present in PJI compared to non-infectious arthroplasty failure based on analysis of transcriptomic data, but their presence in PJI-associated periprosthetic tissues has not been visually confirmed. This preliminary study investigated the presence and activation status of mast cells in periprosthetic tissues associated with PJI. Periprosthetic tissues from five PJI cases and three arthroplasty failures due to instability and one due to stiffness were immunohistochemically stained using tryptase and microscopically evaluated to enumerate mast cells and evaluate overall activation status within tissue samples. Mast cell activation was evidenced by the release of tryptase into the extracellular space surrounding mast cells. Mast cells were found in all samples, with average cellular densities of 22 and 26 cells/mm While preliminary, these findings provide evidence for a role of mast cells in the immune response in PJI. Additional investigation of the role of mast cells during arthroplasty failure is warranted, providing a better understanding of underlying biology and informing potential diagnostic and treatment targets.
Sections du résumé
Background
Periprosthetic joint infection (PJI) is a devastating complication of total joint arthroplasty surgery. Increased densities of activated mast cells have been predicted to be present in PJI compared to non-infectious arthroplasty failure based on analysis of transcriptomic data, but their presence in PJI-associated periprosthetic tissues has not been visually confirmed.
Objective
This preliminary study investigated the presence and activation status of mast cells in periprosthetic tissues associated with PJI.
Methods
Periprosthetic tissues from five PJI cases and three arthroplasty failures due to instability and one due to stiffness were immunohistochemically stained using tryptase and microscopically evaluated to enumerate mast cells and evaluate overall activation status within tissue samples. Mast cell activation was evidenced by the release of tryptase into the extracellular space surrounding mast cells.
Results
Mast cells were found in all samples, with average cellular densities of 22 and 26 cells/mm
Conclusion
While preliminary, these findings provide evidence for a role of mast cells in the immune response in PJI. Additional investigation of the role of mast cells during arthroplasty failure is warranted, providing a better understanding of underlying biology and informing potential diagnostic and treatment targets.
Identifiants
pubmed: 37654491
doi: 10.3389/fimmu.2023.1183977
pmc: PMC10467263
doi:
Substances chimiques
Tryptases
EC 3.4.21.59
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1183977Subventions
Organisme : NIAMS NIH HHS
ID : R01 AR056647
Pays : United States
Organisme : NIGMS NIH HHS
ID : R25 GM055252
Pays : United States
Informations de copyright
Copyright © 2023 Fisher and Patel.
Déclaration de conflit d'intérêts
Author RP reports grants from the companies ContraFect, TenNor Therapeutics Limited, and BIOFIRE. Author RP is a consultant to PhAST, Torus Biosystems, Day Zero Diagnostics, Mammoth Biosciences, and HealthTrackRx; monies are paid to Mayo Clinic. Mayo Clinic and RP have a relationship with Pathogenomix. RP has research supported by Adaptive Phage Therapeutics. Mayo Clinic has a royalty-bearing know-how agreement and equity in Adaptive Phage Therapeutics. RP is also a consultant to Netflix, Abbott Laboratories, Oxford Nanopore Technologies, and CARB-X. In addition, RP has a patent on Bordetella pertussis/parapertussis PCR issued, a patent on a device/method for sonication with royalties paid by Samsung to Mayo Clinic, and a patent on an anti-biofilm substance issued. RP receives honoraria from the NBME, Up-to-Date and the Infectious Diseases Board Review Course. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Eur Orthop Traumatol. 2011 May;1(6):207-217
pubmed: 21837262
Clin Orthop Relat Res. 1996 Jan;(322):158-65
pubmed: 8542692
J Histochem Cytochem. 1989 Oct;37(10):1509-15
pubmed: 2674273
J Arthroplasty. 2018 May;33(5):1309-1314.e2
pubmed: 29551303
Nat Rev Immunol. 2023 Jan;23(1):55-68
pubmed: 35610312
Am J Pathol. 2016 Jan;186(1):4-14
pubmed: 26477818
Int J Mol Sci. 2019 Jun 12;20(12):
pubmed: 31212724
Antibiotics (Basel). 2023 Feb 01;12(2):
pubmed: 36830206
J Bone Joint Surg Am. 2023 Jan 4;105(1):63-73
pubmed: 36574631
Sci Adv. 2019 Jan 02;5(1):eaav0216
pubmed: 30613778
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Biomed Res Int. 2020 Mar 19;2020:9647072
pubmed: 32258161
Sci Rep. 2022 Dec 31;12(1):22627
pubmed: 36587032
J Clin Pathol. 2006 Mar;59(3):298-302
pubmed: 16505282
Immunol Rev. 2007 Jun;217:19-37
pubmed: 17498049
Proc Natl Acad Sci U S A. 2007 Feb 13;104(7):2325-30
pubmed: 17277081
Clin Microbiol Rev. 2014 Apr;27(2):302-45
pubmed: 24696437
Mod Pathol. 1996 Oct;9(10):982-8
pubmed: 8902835
Leuk Res. 2001 Jul;25(7):537-41
pubmed: 11377678
J Orthop Res. 2005 Jul;23(4):942-8
pubmed: 15972256
Front Immunol. 2016 Jan 06;6:620
pubmed: 26779180
N Engl J Med. 2023 Jan 19;388(3):251-262
pubmed: 36652356